Acrobiosystems for English
icon_bulk_orderBulk inquiry/Quick order
0
There is no goods in the shopping cart !
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 0-9
Your Position: Home > CD38

CD38

Brief Information

Name:Lymphocyte differentiation antigen CD38
Target Synonym:EC:3.2.2.6,EC:2.4.99.20,2-Phospho-Cyclic-ADP-Ribose Transferase,Cyclic ADP-Ribose Hydrolase 1,2-Phospho-ADP-Ribosyl Cyclase,NAD(+) Nucleosidase,CD38 Antigen (P45),2-Phospho-ADP-Ribosyl Cyclase/2-Phospho-Cyclic-ADP-Ribose Transferase,Ecto-Nicotinamide Adenine Dinucleotide Glycohydrolase,ADP-Ribosyl Cyclase/Cyclic ADP-Ribose Hydrolase 1,Cluster Of Differentiation 38,CD38 Antigen,EC 2.4.99.20,EC 3.2.2.6,ADPRC1,T10,2 -phospho-ADP-ribosyl cyclase,ADPRC 1,cADPr hydrolase 1,ADP-ribosyl cyclase 1,2 -pho
Number of Launched Drugs:3
Number of Drugs in Clinical Trials:35
Lastest Research Phase:Approved

Product ListCompare or Buy

ACRO Quality

Part of Bioactivity data

CD8-H5224-SPR
 CD38 SPR

Anti-CD38 mAb (Human IgG1) captured on CM5 chip via anti-human IgG Fc antibodies surface, can bind Human CD38, His Tag (Cat. No. CD8-H5224) with an affinity constant of 4.98 nM as determined in a SPR assay (Biacore T200) (Routinely tested).

CD8-H82F5-ELISA
 CD38 ELISA

Immobilized Biotinylated Human CD38, Fc,Avitag (Cat. No. CD8-H82F5) at 1 μg/mL (100 μL/well) on streptavidin (Cat. No. STN-N5116) precoated (0.5 μg/well) plate can bind Monoclonal Anti-CD38 Antibody, Human IgG1 with a linear range of 0.5-8 ng/mL (QC tested).

Customer Reviews

Synonym Name

CD38,T10,cADPr hydrolase 1

Background

CD antigen CD38 is also known as ADP-ribosyl cyclase 1, which belongs to the ADP-ribosyl cyclase family. CD38 is expressed at high levels in pancreas, liver, kidney, brain, testis, ovary, placenta, malignant lymphoma and neuroblastoma. CD38 is a multifunctional ectoenzyme that catalyzes the synthesis and hydrolysis of cyclic ADP-ribose (cADPR) from NAD+ to ADP-ribose. These reaction products are essential for the regulation of intracellular Ca2+. The loss of CD38 function is associated with impaired immune responses, metabolic disturbances, and behavioral modifications. The CD38 protein is a marker of cell activation. It has been connected to HIV infection, leukemias, myelomas, solid tumors, type II diabetes mellitus and bone metabolism. CD38 has been used as a prognostic marker in leukemia.

Clinical and Translational Updates

Public Drug Information

Name Research Code Research Phase Company First Brand Name First Approved Country First Indication First Approved Company First Approved Date Indications Clinical Trials
Isatuximab SAR-650984 Approved Immunogen Inc Sarclisa United States Multiple Myeloma Sanofi-Aventis U.S. Llc 2020-03-02 Anemia, Aplastic; Leukemia, T-Cell; Carcinoma, Non-Small-Cell Lung; Macroglossia; Leukemia, Myeloid, Acute; Lymphoma, Non-Hodgkin; Lymphoma; Nausea; Hepatomegaly; Gastrointestinal Hemorrhage; Satiety Response; Diarrhea; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Precursor T-Cell Lymphoblastic Leukemia-Lymphoma; Hematologic Neoplasms; Anemia, Hemolytic, Autoimmune; Prostatic Neoplasms; Multiple Myeloma; Immunoglobulin Light-chain Amyloidosis; Purpura; Neoplasms; Smoldering Multiple Myeloma; Hodgkin Disease; Lymphadenopathy; Paraproteinemias; Constipation; Goiter, Nodular Details
Daratumumab/Hyaluronidase-fihj Approved Janssen Global Services Llc Darzalex Faspro, Darzquro United States Multiple Myeloma Janssen Biotech Inc 2020-05-01 Peripheral Nervous System Diseases; Multiple Myeloma; Monoclonal Gammopathy of Undetermined Significance; Rejection of organ transplantation; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Precursor T-Cell Lymphoblastic Leukemia-Lymphoma; Amyloidosis; Rejection in heart transplantation Details
Daratumumab JNJ-54767414 Approved Janssen Global Services Llc Darzalex, 兆珂, 兆珂速 United States Multiple Myeloma Janssen Biotech Inc 2015-11-16 Lymphoma, Follicular; Autoimmune Diseases of the Nervous System; Hypersensitivity; POEMS Syndrome; Waldenstrom Macroglobulinemia; Leukemia, Myeloid, Acute; Lymphoma, Non-Hodgkin; Lymphoma; Urologic Neoplasms; Alzheimer Disease; Amyloidosis; Lymphoma, Extranodal NK-T-Cell; Lymphoma, Primary Effusion; Lupus Erythematosus, Systemic; Prostatic Neoplasms; Lymphoma, Mantle-Cell; Purpura, Thrombocytopenic, Idiopathic; Urinary Bladder Neoplasms; Rejection of organ transplantation; Multiple Myeloma; Hodgkin Disease; Glioblastoma; Autoimmune Diseases; Myelodysplastic Syndromes; Immunoglobulin Light-chain Amyloidosis; Lymphoma, Large B-Cell, Diffuse; Smoldering Multiple Myeloma; Paraproteinemias; Genital Neoplasms, Male; Carcinoma, Renal Cell; Kidney Neoplasms; Rejection of renal transplantation Details

Clinical Drug Information

Name Research Code Research Phase Company Indications Clinical Trials
GBR-1342 GBR-1342; ISB-1342 Phase 1 Clinical Glenmark Pharmaceuticals Ltd Multiple Myeloma Details
CART-38 CART-38 Phase 2 Clinical The First Affiliated Hospital Of Soochow University Leukemia, Myeloid, Acute Details
Mezagitamab TAK-079 Phase 2 Clinical Takeda Purpura, Thrombocytopenic, Idiopathic; Myasthenia Gravis; Hematologic Neoplasms; Nephrosis; Glomerulonephritis, IGA; Kidney Diseases; Autoimmune Diseases; Multiple Myeloma; Lupus Erythematosus, Systemic; Thrombocytopenia; Glomerulonephritis Details
ISB-2001 ISB-2001 Phase 1 Clinical Ichnos Sciences Sa Multiple Myeloma Details
64Cu-DOTA-daratumumab Phase 1 Clinical City Of Hope National Medical Center Multiple Myeloma Details
STI-6129 STI-6129; LNDS-1001 Phase 2 Clinical Sorrento Therapeutics Inc Solid tumours; Immunoglobulin Light-chain Amyloidosis; Multiple Myeloma; Precursor T-Cell Lymphoblastic Leukemia-Lymphoma; Leukemia, Myeloid, Acute Details
TAK-169 TAK-169; MT-0169 Phase 1 Clinical Molecular Templates Inc Multiple Myeloma Details
Y-150(Wuhan Yzy Biopharma/CSPC Pharmaceutical) Y-150; Y150 Phase 1 Clinical Wuhan Yzy Biopharma Co Ltd, CSPC Pharmaceutical Group Ltd Multiple Myeloma Details
Universal CAR-T Cells therapy(Shenzhen Geno-Immune Medical Institute) Phase 1 Clinical Shenzhen Geno-Immune Medical Institute Leukemia, Myeloid, Acute Details
CART-38(University of Pennsylvania) CART-38 Phase 1 Clinical University Of Pennsylvania Multiple Myeloma; Leukemia, Myeloid, Acute Details
CLL1 and CD38 Dual CAR-T therapy(Gracell Biotechnologies) Phase 1 Clinical Gracell Biotechnologies (Shanghai) Co Ltd, The 920th Hospital Of Joint Logistics Support Force Of PLA Leukemia, Myeloid, Acute Details
211At-OKT10-B10 Phase 1 Clinical Fred Hutchinson Cancer Research Center Multiple Myeloma Details
Daratumumab biosimilar (Hangzhou Jiuyuan Gene Engineering) Phase 1 Clinical Hangzhou Jiuyuan Gene Engineering Co Ltd Multiple Myeloma Details
Modakafusp alfa TEV-48573; TAK-573 Phase 2 Clinical Takeda Pharmaceutical Co Ltd Neoplasms; Multiple Myeloma; Melanoma Details
Anti-CD38 chimeric antigen receptor T cell therapy(Yake Biotechnology) CAR-T CD-38 Phase 1 Clinical Shanghai YaKe Biotechnology Co Ltd Multiple Myeloma; Leukemia, Myeloid, Acute Details
4SCAR-T cell therapy (Shenzhen Geno-Immune Medical Institute) 4SCAR-T Phase 2 Clinical Shenzhen Geno-Immune Medical Institute Hematologic Neoplasms; Autoimmune Diseases; Neuroblastoma Details
CD38-SADA:177 Lu-DOTA Drug Complex Phase 1 Clinical Y-Mabs Therapeutics Inc Lymphoma, Non-Hodgkin Details
89Zr-DFO-daratumumab Phase 2 Clinical Memorial Sloan Kettering Cancer Center Multiple Myeloma Details
Anti CD38 chimeric antigen receptor T-cell therapy (Sorrento Therapeutics) Phase 1 Clinical Celularity Inc, Sorrento Therapeutics Inc Multiple Myeloma Details
SG-2501 SG-2501 Phase 1 Clinical Hangzhou Sumgen Biotechnology Co Ltd Hematologic Neoplasms; Lymphoma Details
CID-103 CID-103; TSK011010 Phase 1 Clinical Tusk Therapeutics Ltd Multiple Myeloma Details
KP-1237 Phase 2 Clinical Biohaven Pharmaceuticals Inc Multiple Myeloma Details
Anti-BCMA anti-CD38 bispecific chimeric antigen receptor T cell therapy (Shengyan Pharmaceutical Technology) Phase 1 Clinical Shengyan Pharmaceutical Technology, Wuhan Union Hospital Multiple Myeloma Details
TNB-738 TNB-738 Phase 1 Clinical TeneoFour Inc Details
Daratumumab biosimilar (Henlius) HLX-15 Phase 1 Clinical Shanghai Henlius Biologics Co Ltd Multiple Myeloma Details
XmAb-18968 XmAb-18968 Phase 1 Clinical The Medical College Of Wisconsin Nonprofit Leukemia, Myeloid, Acute Details
ISB-1442 ISB 1442; ISB-1442 Phase 2 Clinical Ichnos Sciences Sa Multiple Myeloma; Precursor T-Cell Lymphoblastic Leukemia-Lymphoma; Leukemia, Myeloid, Acute Details
Felzartamab MOR-03087; TJ-202; MOR-202; HBIB-202 Phase 3 Clinical Morphosys Ag Glomerulonephritis, IGA; Glomerulonephritis, Membranous; Rejection of organ transplantation; Multiple Myeloma; Lupus Nephritis; Lupus Erythematosus, Systemic; Glomerulonephritis Details
Lumrotatug CM-313 Phase 2 Clinical Keymed Biosciences Co Ltd Hematologic Neoplasms; Multiple Myeloma; Lupus Erythematosus, Systemic; Lymphoma Details
Anti-CD38 Antibody(Institute of Hematology & Blood Diseases Hospital) Phase 2 Clinical Institute Of Hematology & Blood Diseases Hospital Purpura, Thrombocytopenic, Idiopathic; Antiphospholipid Syndrome Details
XmAb-968 XmAb968 Phase 1 Clinical Xencor Inc Hematologic Neoplasms; Leukemia, Promyelocytic, Acute Details
Erzotabart GEN-3014 Phase 2 Clinical Genmab A/S Lymphoma, Large B-Cell, Diffuse; Multiple Myeloma; Leukemia, Myeloid, Acute Details
SAR-442257 SAR-442257 Phase 1 Clinical Sanofi Neoplasms Details
Recombinant human anti-CD38 momoclonal antibody(Sumgen) SG-301; SG301 Phase 1 Clinical Hangzhou Sumgen Biotechnology Co Ltd Hematologic Neoplasms; Multiple Myeloma; Lupus Erythematosus, Systemic Details

This web search service is supported by Google Inc.

totop
Call us
Call us
North America:
+1 800-810-0816 (Toll Free)
Asia & Pacific:
+86 400-682-2521
Fax
Fax
+1 888-377-6111
Address
Address
1 Innovation Way, Newark, DE 19711, USA

Leave a message